Brand Name

Halaven

Generic Name
Eribulin
View Brand Information
FDA approval date: November 15, 2010
Classification: Microtubule Inhibitor
Form: Injection, Solution

What is Halaven (Eribulin)?

Eribulin Mesylate Injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Who is this study for: Patients with metastatic urothelial carcinoma refractory to, or ineligible for, anti PD1/PDL1 therapy
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3

Summary: This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, eithe...

A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, and TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH AR+ METASTATIC TRIPLE-NEGATIVE OR ER-LOW BREAST CANCER
A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, and TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH AR+ METASTATIC TRIPLE-NEGATIVE OR ER-LOW BREAST CANCER
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, pacl...

A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.

View All Clinical Trials

Related Latest Advances

Reporting Matters: Severe Adverse Events in Soft Tissue Sarcoma Therapy-A 30-Year Systematic Review of Placebo- and Non-Systemic-Controlled Randomized Trials.
Reporting Matters: Severe Adverse Events in Soft Tissue Sarcoma Therapy-A 30-Year Systematic Review of Placebo- and Non-Systemic-Controlled Randomized Trials.
Journal: Cancers
Published: August 18, 2025
KSHV and HPV modulate epithelial-to-mesenchymal transition in oral epithelial cells.
KSHV and HPV modulate epithelial-to-mesenchymal transition in oral epithelial cells.
Journal: mBio
Published: August 15, 2025
Eribulin in metastatic breast cancer in the real-world - the way forward in the Indian setting.
Eribulin in metastatic breast cancer in the real-world - the way forward in the Indian setting.
Journal: Journal of chemotherapy (Florence, Italy)
Published: August 07, 2025
View All Latest Advances

Brand Information

Halaven (eribulin mesylate)
1DOSAGE FORMS AND STRENGTHS
Injection:  1 mg/2 mL (0.5 mg/mL) eribulin mesylate is a clear, colorless, sterile solution in a single-dose vial. 
2CONTRAINDICATIONS
None.
3OVERDOSAGE
Overdosage of HALAVEN has been reported at approximately 4 times the recommended dose, which resulted in Grade 3 neutropenia lasting seven days and a Grade 3 hypersensitivity reaction lasting one day.
There is no known antidote for HALAVEN overdose.
4DESCRIPTION
HALAVEN contains eribulin mesylate, a microtubule dynamics inhibitor. Eribulin mesylate is a synthetic analogue of halichondrin B, a product isolated from the marine sponge 
a product isolated from the marine sponge Halichondria okadai. The chemical name for eribulin mesylate is 11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-i]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate (salt). It has a molecular weight of 826.0 (729.9 for free base). The empirical formula is C40H59NO11•CH4O3S. Eribulin mesylate has the following structural formula:
HALAVEN is a clear, colorless, sterile solution for intravenous administration. Each single-dose vial contains 1 mg of eribulin mesylate in 2 mL of solution. Each mL of solution contains 0.5 mg of eribulin mesylate (equivalent to 0.44 mg eribulin) in dehydrated alcohol (5% v/v) and water for injection (95% v/v). Sodium hydroxide or hydrochloric acid may be used for pH adjustment.
5REFERENCES
1. OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html
6HOW SUPPLIED/STORAGE AND HANDLING
NDC 62856-389-01      
Injection: 1 mg/2 mL, in a single-dose vial. One vial per carton.
Store at 25°C (77°F); excursions permitted to 15° to 30° C (59° to 86° F). Do not freeze or refrigerate. Store the vials in their original cartons.
HALAVEN injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.¹
7PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling
Neutropenia
Advise patients to contact their health care provider for a fever of 100.5°F or greater or other signs or symptoms of infection such as chills, cough, or burning or pain on urination 
Peripheral Neuropathy
Advise patients to inform their healthcare providers of new or worsening numbness, tingling and pain in their extremities
Embryo-Fetal Toxicity
  • Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy
  • Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks after the final dose
  • Advise males with female partners of reproductive potential to use effective contraception
Lactation
Advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose
Distributed by:
© 2010-2022 Eisai Inc.